| Basic data |
|---|
| OCA1. Surname awarded to the assessed person | Novotný |
|---|
| OCA2. Name awarded to the assessed person | Jaroslav |
|---|
| OCA3. Degrees awarded to the assessed person | Assoc. prof. , DVM, PhD |
|---|
| OCA4. Hyperlink to the entry of the person in the Register of university staff | https://www.portalvs.sk/regzam/detail/6072 |
|---|
| OCA5. Area of assessment | study programme general veterinary medicine · I. + II. degree |
|---|
| OCA6. Category of the research/artistic/other output | scientific output |
|---|
| OCA7. Year of publication of the research/artistic/other output | 2025 |
|---|
| OCA8. ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) | 1376207 |
|---|
| OCA9. Hyperlink to the record in CRPA or CRAA | https://app.crepc.sk/?fn=detailAutorFormChildCBHLE&sid=B8E5C3537597C450303CCCF82D&seo=CREP%C4%8C-detail-osoby |
|---|
| Characteristics of the output that is not registered in CRPA or CRAA |
|---|
| OCA10. Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs | https://www.sciencedirect.com/science/article/pii/S0022354925002680 |
|---|
| OCA11. Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs | Tailored biopolymer capsules for colon-specific drug delivery: A 3D printing perspective / Muselík, Jan [Autor, 10%] ; Komersová, Alena [Autor, 5%] ; Elbl, Jan [Autor, 5%] ; Svoboda, Roman [Autor, 5%] ; Matzick, Kevin [Autor, 5%] ; Macháčková, Jana [Autor, 5%] ; Nevyhoštěná, Marie [Autor, 5%] ; Krepelková, Zuzana [Autor, 5%] ; Novotný, Jaroslav [Autor, 50%] ; Franc, Aleš [Autor, 5%]. – [recenzované]. – DOI 10.1016/j.xphs.2025.103815. – SCO.
In: Journal of Pharmaceutical Sciences [textový dokument (print)] : a publication of the American Pharmaceutical Association. – Washington (USA) : American Pharmaceutical Association. – ISSN 0022-3549. – ISSN (online) 1520-6017. – Roč. 114, č. 7 (2025), art. no. 103815, s. [1-13] [tlačená forma] |
|---|
| OCA12. Type of the output (if the output is not registered in CRPA or CRAA) | article |
|---|
| OCA13. Hyperlink to the webpage where the output is available (full text, other documentation, etc.) | https://www.sciencedirect.com/science/article/pii/S0022354925002680 |
|---|
| OCA14. Characteristics of the author's contribution | Conceptualization, Methodology, Investigation, Funding acquisition, Writing – review & editing. |
|---|
| OCA15. Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. | The present study aims to develop capsules employing hot melt extrusion (HME) and fused deposition modeling (FDM) three-dimensional (3D) printing approach. The primary objective was to establish a colon drug delivery system (CDDS) based on multiple release mechanisms. In the study, 3D printed hydroxypropylmethylcellulose (HPMC) based capsules containing polysaccharides (alginate, chitosan pectin from citrus and pectin from apple) were used to provide a time-triggered and microbiota-triggered release mechanism. Thirteen capsule compositions were tested, and physico-chemical properties, disintegration time, dissolution characteristic (lag time) and 50 days accelerated stability were assessed. In addition, an enteric coating by Eudragit S was tested to enhance protection against the gastric environment. Disintegration time of the capsule under in vivo conditions was verified in healthy volunteers by oral administration of the caffeine-loaded capsule and determination of the first-appearance time of caffeine in the saliva. Furthermore, in vivo monitoring of the transition time in piglets was performed by X-ray examination after oral administration of BaSO4-loaded capsules. Optimal capsule composition was identified as HPMC and pectin from citrus in 80:20 wt% ratio. Printed capsules showed suitable physico-chemical properties, lag time and stability. Minimal drug release in the upper gastrointestinal tract (∼5 %) for the first 8–10 h was ensured by both coated and uncoated capsules. In addition, as demonstrated by the in vivo transition time monitoring assay, with accelerated passage of the capsule through the gastrointestinal tract, degradation is significantly accelerated (∼4 h) by a microbiota-triggered mechanism, effectively targeting the colon. Using 3D printing, a colonic-specific drug delivery system was prepared that could potentially be suitable for treating patients with various intestinal physiological conditions. |
|---|
| Other data |
|---|
| OCA16. Annotation of the output in English | |
|---|
| OCA17. List of maximum 5 most significant citations corresponding to the output | |
|---|
| OCA18. Characteristics of the output's impact on socio-economic practice | Encapsulation of the fecal microbiota transplant into biopolymer particles provides bacteria with a higher degree of protection and increased efficacy. The encapsulation process protects the bioactive components not only from degradative factors of the surrounding environment during their passage through the gastrointestinal tract and supports the release of the cargo at the target site under specific conditions at a controlled rate (pH change, enzymatic activity, ionic strength variation, temperature change), but also safeguards the bioactive components during stabilization, storage at various temperatures, and significantly prolongs their shelf life. |
|---|
| OCA19. Characteristics of the output and related activities' impact on the educational process | The publication is suitable study literature for students of the general veterinary medicine and food hygiene study program. |
|---|
